ProPhase Diagnostics

ProPhase Diagnostics is a healthcare diagnostics subsidiary/business of ProPhase Labs focused on clinical laboratory testing and diagnostic services. The business historically operated CLIA-certified laboratory capabilities supporting COVID-19 and respiratory pathogen testing, and ProPhase has also highlighted development and commercialization efforts around its BE-Smart esophageal cancer-related diagnostic test. In public disclosures, ProPhase positioned diagnostics alongside genomics and consumer health as part of a broader diversified healthcare strategy. By 2025, parts of the legacy diagnostics structure entered Chapter 11 proceedings, while the parent company continued to emphasize a leaner focus on selected growth assets. For a biotech analyst, ProPhase Diagnostics is best understood as a commercial diagnostics operation within the ProPhase ecosystem rather than a therapeutics developer.